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A B S T R A C T
Neutrophils are the first line of defense in the innate immune system, helping to maintain tissue homeostasis as
well as eliminating pathogens and self-components. The traditional view of neutrophils as simple phagocytes has
been revised over the last decade as new research reveals their unappreciated complexity. Neutrophils are
phenotypically and functionally heterogeneous, allowing them to act as modulators of both inflammation and
immune responses. During acute inflammation, neutrophils perform a variety of beneficial effector functions, but
when inflammation is induced by injury (sterile inflammation) the benefits of neutrophils in tissue repair are
more controversial. In several pathological conditions, including cancer and autoimmune diseases, neutrophils
can trigger harmful tissue damage. Interestingly, neutrophils are also key players in neuroinflammatory dis-
orders, during which they transmigrate in the central nervous system, acquire a toxic phenotype, home in on
neurons, and release harmful molecules that compromise neuronal functions. In this review, we discuss recent
data that redefine the cell biology and phenotype of neutrophils, focusing on the role of these cells in multiple
sclerosis and Alzheimer’s disease, both of which feature strong neuroinflammatory components.
1. Introduction
Neutrophils, basophils and eosinophils together comprise the poly-
morphonuclear leukocytes (PMNs), also known as granulocytes because
of their abundant cytoplasmic granules (Roitt et al., 2001). These ex-
ceptionally sensitive leukocytes are the first line of defense in the innate
immune system, with key roles in the maintenance of tissue home-
ostasis (Mantovani et al., 2011), and the elimination of pathogens and
self-components, including nucleic acids and the products of sterile
tissue damage (Kolaczkowska and Kubes, 2013).
Until about 10 years ago, neutrophils were considered to be a
homogenous population of short-lived, nonproliferative and terminally
differentiated cells with reduced transcriptional capacity, producing a
limited panel of cytokines, and with no ability to recirculate from tis-
sues to blood, suggesting highly conserved specialized functions.
However, more recent research based on powerful high throughput
technologies and computing data analysis methods has revealed un-
expected phenotypic plasticity and diversity in terms of neutrophil
trafficking and functionality. Their role is now understood to include
not only homeostasis but also inflammation and tissue damage that, if
not resolved, could lead to autoimmune diseases and chronic in-
flammatory conditions (Nemeth et al., 2016; Ley et al., 2018).
During acute inflammation caused by infection, the effector
functions of neutrophils are generally beneficial to the host. However,
when injury induces sterile inflammation, the effect of neutrophils is
more complex, and can include chronic tissue damage in patients with
cancer and autoimmune disorders (Kubes, 2018). Neurodegenerative
diseases are also exacerbated by neutrophils, which produce in-
flammatory messages when they infiltrate the central nervous system
(CNS) and make contact with neuronal cells, leading to a complex series
of events that ultimately result in neuronal death. Notably, neutrophils
play a pivotal role in several sterile neuroinflammatory diseases, such
as trauma, cerebral ischemia, demyelinating syndromes but also in in-
fectious conditions such as viral and bacterial encephalitis (Miller et al.,
2015; Kenne et al., 2012; Holmin et al., 1998). Once extravasated in the
CNS parenchyma, neutrophils likely contact neuronal cells and release
damaging molecules that may impair neuronal physiology (Allen et al.,
2012). Limiting neutrophil migration and/or activity could therefore
ameliorate neurodegeneration by reducing neuronal injury (Miller
et al., 2015; Kenne et al., 2012; Zenaro et al., 2015, 2017).
Neurodegenerative conditions, including Alzheimer’s disease (AD),
multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and
Parkinson’s disease (PD), are characterized by uncontrolled neuronal
death that leads to a progressive decline in brain functions, such as
cognition and locomotor control. The affected brain areas may differ
between disorders, leading to a wide spectrum of clinical
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manifestations. However, the growing incidence of neurodegenerative
diseases represents an increasing burden on health care systems
worldwide due to the limited availability of effective therapies.
Neurodegenerative diseases such as AD and ALS are currently un-
treatable, and future treatment strategies will require the simultaneous
targeting of multiple pathogenic components in order to reduce neu-
ronal loss. Neurodegenerative diseases also have a complex etiology,
with multiple risk factors contributing to susceptibility including aging,
genetic factors and environmental triggers. Our understanding of the
specific pathways and molecular mechanisms involved in these dis-
orders remains rudimentary at best, and a more comprehensive un-
derstanding of neurodegenerative pathology will require a broadening
of the current neurocentric viewpoint.
The role of neuroinflammation in neurodegenerative diseases in-
dicates that the dysregulation of the immune system is an important
etiological factor. There is a large body of evidence that MS is asso-
ciated with aberrant gene expression in cells of the innate and adaptive
immune systems (Hellings et al., 2002; Hernandez-Pedro et al., 2013),
but such associations have only recently been reported for the other
neurodegenerative diseases discussed above (Gagliano et al., 2016;
Yokoyama et al., 2016). For example, a recent genome-wide association
study (GWAS) involving MS, PD, ALS and AD patients revealed strong
associations between PD and genes expressed in adaptive immune cells
(such as T cells), whereas MS and AD were associated with genes ex-
pressed in the adaptive and innate immune systems, the latter including
CD14 in monocytes and CD15 in neutrophils (Gagliano et al., 2016).
Although AD and MS have distinct clinical symptoms, they share si-
milar immune cell signatures characterized by the involvement of
neutrophils in pathogenesis.
This review brings together recent data that redefines neutrophil
biology and phenotype, focusing on the roles of neutrophils in neuro-
degenerative diseases with a chronic neuroinflammatory component.
We summarize what is known about the involvement of neutrophils in
the pathogenesis and maintenance of MS, AD, PD and ALS by focusing
on their detrimental effects, particularly the exacerbation of brain in-
jury.
2. The complexity of neutrophils
2.1. Neutrophil biology
Neutrophils are the most abundant leukocytes in mammalian blood,
representing 50–70% of all leukocytes in humans and 10–25% in mice
(Mestas and Hughes, 2004). As well as neutrophils in the circulation,
another population of mature neutrophils is found in a marginated
state, slowly transiting in the vascular compartments of bone marrow
sinusoids, the spleen, liver, and lungs, and in some interstitial tissues
(Summers et al., 2010). More than 50 years ago, it was estimated that
49% of human neutrophils were found in the blood and 51% as mar-
ginated cells (Athens et al., 1961), whereas in mice only 1–2% of
neutrophils are found in the circulation and the remainder as margi-
nated cells or cell stored in the bone marrow hematopoietic compart-
ment (Semerad et al., 2002). Neutrophils are normally short-lived cells
with a circulating half-life of 8–12.5 h in mice (Pillay et al., 2010a,b,
Lord et al., 1991; Basu et al., 2002) and 5 h to 5.4 days in humans
(Pillay et al., 2010a,b, Lahoz-Beneytez et al., 2016; Pillay et al., 2012).
However, recent studies suggest that the activation of neutrophils
during inflammation increases their longevity, allowing them to carry
out more complex activities than previously understood (Deniset and
Kubes, 2016).
In adult bone marrow under basal conditions, neutrophils mature
from common hematopoietic CD34+ stem cells (Lahoz-Beneytez et al.,
2016) in a process called granulopoiesis, which takes ∼5 days (Athens
et al., 1961; Lahoz-Beneytez et al., 2016; Dancey et al., 1976; Macallan
et al., 1998). Under these conditions, the generation rate is 5–10× 1010
cells per day, to compensate for the short half-life in circulation (Roitt
et al., 2001; Summers et al., 2010). Granulopoiesis is a multi-step
process involving three main stages of developmental commitment: (i)
the undifferentiated stem cell pool, consisting of hematopoietic stem
cells and pluripotent progenitors; (ii) the intermediate lineage-com-
mitted mitotic pool, comprising actively proliferating myeloblasts,
promyelocytes, and myelocytes; (iii) and the post-mitotic pool, mainly
comprising fully-differentiated, mature neutrophils (Summers et al.,
2010; Semerad et al., 2002). Neutrophil development involves the
condensation and hyper-segmentation of the nucleus and the formation
of cytoplasmic granules, both of which are useful morphological mar-
kers that identify mature neutrophils. In contrast, immature neutrophils
are characterized by a kidney-shaped nucleus in humans, and a ring-
shaped nucleus in mice (Rausch and Moore, 1975; Lemez and
Kacirkova, 2014; Pillay et al., 2013). Granulopoiesis is regulated by
several cytokines and growth factors released from hematopoietic and
stromal cells, particularly granulocyte colony-stimulating factor (G-
CSF), granulocyte macrophage colony-stimulating factor (GM-CSF),
stem cell factor (SCF), interleukin 3 (IL-3), IL-6, and FMS-like tyrosine
kinase 3 ligand (FLT3-L) (Manz and Boettcher, 2014), together with
reactive oxygen species (ROS) (Zhu et al., 2017). Under physiological
conditions, G-CSF is the principal regulator of neutrophil production
and release from the bone marrow (Summers et al., 2010; Bugl et al.,
2012). The retention or release of neutrophils from bone marrow de-
pends on the expression of certain CXC-motif chemokine receptors
(CXCR family) on the surface of neutrophils and their interaction with
secreted CXC ligands (CXCL family). Neutrophil storage is maintained
when receptor CXCR4 binds CXCL12/stromal cell-derived factor 1
(SDF-1) produced by hematopoietic stem cells and bone marrow
stromal cells (Furze and Rankin, 2008). Neutrophil release is promoted
when CXCR4 is replaced with CXCR2, following peripheral attraction
by chemokines (Martin et al., 2003; Eash et al., 2010; Devi et al., 2013;
Christopher et al., 2009). In this context, G-CSF induces neutrophil
mobilization by suppressing the expression of CXCR4 and inhibiting the
production of CXCL12 by stromal cells (Semerad et al., 2002; De La Luz
Sierra et al., 2007; Kim et al., 2006). Mature neutrophils leave the
hematopoietic parenchyma for the blood stream primarily by trans-
cellular migration through the tight-fitting pores of sinusoidal en-
dothelial cells (Burdon et al., 2008).
Under basal conditions and during inflammation, apoptotic neu-
trophils are removed from clearance sites by macrophages, which de-
stroy them by phagocytosis (Serhan and Savill, 2005). Given the effi-
ciency with which the hematopoietic compartment continuously
produces and releases large numbers of neutrophils, it is evident that
efficient clearance is necessary for homeostasis. Studies in mice and
human volunteers have shown how radiolabeled circulating neutrophils
are captured and subsequently destroyed by reticular endothelial
macrophages in the spleen, liver and bone marrow, each of them con-
tributing equally (∼30% each) to neutrophil clearance (Furze and
Rankin, 2008; Thakur et al., 1977; Saverymuttu et al., 1985; Lovas
et al., 1996; Suratt et al., 2001; Rankin, 2010; Shi et al., 2001). How-
ever, the bone marrow makes the greatest contribution to homeostatic
neutrophil clearance under steady-state conditions (Furze and Rankin,
2008). In the spleen and liver, the reticular endothelial system is pre-
cisely located to ensure the direct capture of circulating apoptotic cells,
whereas senescent neutrophils in the bone marrow reach stromal
macrophages that are located within the hematopoietic tissue by active
migration through the sinusoidal endothelium (Martin et al., 2003).
Pre-apoptotic senescent circulating neutrophils display high levels of
CXCR4 and low levels of CXCR2, which reduces their ability to follow
peripheral chemokines such as CXCL1, CXCL2, CXCL5 and CXCL8
(Christopher et al., 2009) while enhancing their CXCL12-dependent
migration in the hematopoietic compartment (Martin et al., 2003;
Nagase et al., 2002). Intriguingly, whereas efferocytosis stimulates re-
solution processes during the clearance of cells from inflammatory sites
(Serhan and Savill, 2005; Fadok et al., 1998), the destruction of se-
nescent neutrophils in the bone marrow stimulates resident stromal
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macrophages to secrete GCSF, increasing the circadian release of he-
matopoietic progenitors into the circulation during homeostasis
(Casanova-Acebes et al., 2013). In healthy subjects, the neutrophil
count is maintained by homeostatic equilibrium between production,
storage, mobilization (from bone marrow or intravascularly marginated
pools) and clearance (Bugl et al., 2012). G-CSF is mainly responsible for
neutrophil homeostasis, not only by controlling granulopoiesis and
mobilization, but also by regulating neutrophil trafficking and lifespan
(Semerad et al., 2002; Basu et al., 2002; Lieschke et al., 1994).
Many environmental factors, including drugs, physical exercise,
prolonged inflammation and infections affect the maturation, activation
status and lifespan of neutrophils (Summers et al., 2010; Bugl et al.,
2012). During infection and/or inflammation, neutrophils are rapidly
mobilized from bone marrow, increasing their abundance in the cir-
culation by up to 10-fold within a matter of hours. Chemokines that are
released locally at sites of inflammation and regulate the recruitment of
circulating leucocytes into tissues also promote neutrophil mobilization
(Kobayashi, 2006). Studies in animal models have shown that high
plasma levels of several chemokines (including CXCL1, CXCL2 and
CXCL8) and other chemotactic factors (including leukotrienes B4 and
C5a) induce neutrophilia by inducing rapid neutrophil mobilization
from the bone marrow (Burdon et al., 2008; Terashima et al., 1998;
Wengner et al., 2008; Jagels et al., 1995; Jagels and Hugli, 1992).
Mobilization is also enhanced by the indirect effect of G-CSF, which
reduces the availability of CXCL12 and the expression of CXCR4, thus
freeing neutrophils to respond to peripheral chemoattractants (Martin
et al., 2003). Systemic infections, prolonged inflammation or conditions
that trigger myeloablation can rapidly induce bone marrow to release
immature neutrophils from the post-mitotic pool, which accounts for
95% of the total neutrophil population (Summers et al., 2010; Semerad
et al., 2002). This process of accelerated neutrophil production is
known as emergency granulopoiesis, and the immature neutrophils are
directly stimulated following the recognition of microbial associated
molecular patterns (PAMPs) or damage associated molecular patterns
(DAMPs) (Manz and Boettcher, 2014, Bugl, et al., 2012, Balmer et al.,
2014). However, these immature circulating neutrophils do not contain
the full complement of granules (Rausch and Moore, 1975), and they
are less active than mature neutrophils, producing lower quantities of
ROS and antimicrobial peptides, and with a lower capacity for phago-
cytosis, chemotaxis and tissue migration (Kolaczkowska and Kubes,
2013; Suratt et al., 2001; Evrard et al., 2018; Pedersen et al., 2016).
Once mobilized, a proportion of the neutrophil population is en-
listed as the marginated pool, which disappears from the bloodstream,
whereas the remaining neutrophils passively circulate in the blood to be
recruited immediately after infection or injury based on their priming
by circulating DAMPs, PAMPs, cytokines and chemokines (Hallett and
Lloyds, 1995). Circulating cells are attracted to peripheral tissues by
local chemokines that orchestrate their adhesion, transmigration and
chemotaxis at the injury or infection site (Roitt et al., 2001; Kobayashi,
2006). Chemokine signaling activates integrins found in great abun-
dance on the neutrophil plasma membrane, such as lymphocyte func-
tion-associated antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1),
allowing the firm arrest of neutrophils on vessel endothelial cells
(Kolaczkowska and Kubes, 2013). The neutrophils then extend pseu-
dopods to scan the endothelium, seeking an appropriate site for trans-
migration through endothelial cell–cell junctions (paracellular trans-
migration) (Jenne et al., 2013). Following this process of extravasation,
neutrophils follow a second, more attractive chemotactic gradient to
reach the site of inflammation (Phillipson and Kubes, 2011; Foxman
et al., 1997). Local microbes and/or tissue stress factors then induce
signaling pathways in the neutrophils, triggering their antimicrobial
defense and pro-inflammatory programs. The corresponding effector
functions include phagocytosis, the release of neutrophil extracellular
traps (NETs) (Brinkmann et al., 2004) followed by auto-phagocytosis
and intracellular digestion (Mitroulis et al., 2010; Mihalache and
Simon, 2012), the production and release of ROS, antimicrobial
peptides and serine proteases, and the secretion of pro-inflammatory
cytokines and chemokines (Teng et al., 2017). Furthermore, in-
flammasome activation by chemokines and DAMPs also triggers neu-
trophil infiltration during sterile inflammation, where they can induce
acute or chronic inflammatory responses (McDonald et al., 2010).
At the site of inflammation, many neutrophils undergo apoptosis
and are cleared by macrophages and dendritic cells (DCs), leading to
the resolution of acute inflammation and the restoration of tissue
homeostasis (Savill et al., 1989). Neutrophils also contribute actively to
resolution by the degradation of local inflammatory cytokines, the
clearance of DAMPs, the production of cytokines (such as IL-1Ra, IL-10,
IL-1β and IL-6) and lipid mediators, and the secretion of chemokines
such as monocyte chemoattractant protein-1 (MCP-1), which attracts
circulating monocytes and induces a regulatory M2 phenotype in
macrophages (Kolaczkowska and Kubes, 2013; Soehnlein et al., 2009;
Langereis et al., 2011; Wang and Arase, 2014; Butterfield et al., 2006;
Kobayashi, 2015; Headland and Norling, 2015). Furthermore, many
recent studies have reported that neutrophils can return to the blood
after tissue migration (reverse transmigration), and that such cells ex-
hibit a pro-inflammatory phenotype, characterized by the strong ex-
pression of intercellular adhesion molecule-1 (ICAM-1), which corre-
lates with the depletion of junctional adhesion molecule C (JAM-C) in
endothelial cells (Woodfin et al., 2011; Buckley et al., 2006; Shelef
et al., 2013; Colom et al., 2015). Interestingly, reverse-transmigrating
cells are resistant to apoptosis, and this prolonged lifespan may influ-
ence their phenotype and function, thus contributing to neutrophil
heterogeneity (Buckley et al., 2006). The purpose of reverse transmi-
gration is not clearly understood: although it may preserve neutrophils
when they are not needed to fight infection, cells re-entering the cir-
culation could disseminate inflammation to other organs, eventually
leading to damage and/or chronic inflammation (Kolaczkowska and
Kubes, 2013). Alternatively, activated neutrophils may leave infected/
inflamed tissues by migrating to secondary lymphoid organs through
the lymphatic and circulatory systems (Abadie et al., 2005; Chtanova
et al., 2008; Duffy et al., 2012; Gorlino et al., 2014; Hampton et al.,
2015; Yang et al., 2010; Yang and Unanue, 2013). Neutrophils that
egress from tissues to the circulation or emigrate into secondary lym-
phoid organs have a prolonged lifespan and a different phenotype,
explaining their heterogeneous characteristics. Furthermore, during
infection and sterile inflammation, cytokines, PAMPs, DAMPs and other
microenvironmental factors such as serpins may regulate the longevity
of neutrophils by inhibiting apoptosis (Summers et al., 2010; Geering
et al., 2013; Sundqvist et al., 2013; Baumann et al., 2013; Loison et al.,
2014). Indeed, in several chronic inflammatory diseases (such as
asthma and acute coronary syndrome), neutrophil longevity is asso-
ciated with more severe symptoms and a negative prognosis (Uddin
et al., 2010; Garlichs et al., 2004). The extended lifespan of neutrophils
during inflammation may allow phenotypic and functional changes that
underpin the observed heterogeneity in this population (Peyssonnaux
et al., 2005; Thompson et al., 2014; Laval et al., 2013; Makam et al.,
2009). Although the transcriptional plasticity of neutrophils was tra-
ditionally considered rather limited (Cassatella, 1995), recent studies
have reported the inducible genetic and epigenetic modulation of
neutrophil gene expression (Tecchio et al., 2014; Yost et al., 2004), and
the association of both mechanisms with disease susceptibility
(Naranbhai et al., 2015; Coit et al., 2015). Neutrophils secrete a wide
range of chemokines and cytokines either constitutively or in response
to different local stimuli (Tecchio et al., 2014; Cassatella et al., 1992).
This reveals that neutrophils show significant functional diversity in
terms of recruitment, the regulation of controlled sequential migration,
and the activation of other innate and adaptive immune cells such as
monocytes, macrophages, DCs, natural killer (NK) cells, and subsets of
helper T cells, such as Th17 (Mayadas et al., 2014; Jaillon et al., 2013;
Scapini and Cassatella, 2014; Sadik et al., 2011; Pelletier et al., 2010).
Neutrophils may not only attract other cell types but also modulate
their activity, thereby playing a key role in the control of adaptive
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immune responses (Mantovani et al., 2011; Scapini and Cassatella,
2014; Mocsai, 2013). Neutrophils not only activate antigen presenting
cells (APCs) and T cells by secreting pro-inflammatory cytokines and
chemokines (Mantovani et al., 2011; Wright et al., 2010), but may also
function directly as APCs (Hampton et al., 2015; Yang et al., 2010; Yang
and Unanue, 2013; Cross et al., 2003). In the synovial fluid of rheu-
matoid arthritis patients, neutrophils were found to express high levels
of major histocompatibility complex (MHC)-II and costimulatory mo-
lecules such as CD80 and CD89, which enabled them to stimulate T cell
proliferation in vitro (Cross et al., 2003). Furthermore, if neutrophils
are prevented from migrating to the lymph nodes in mouse disease
models, the proliferation of T cells is inhibited, suggesting that neu-
trophils can initiate early adaptive immune responses (Hampton et al.,
2015; Yang et al., 2010; Yang and Unanue, 2013). Other studies have
proposed that neutrophils with internalized microbes may act as
“Trojan vectors” for macrophages (Coombes et al., 2013; Peters et al.,
2008). Some circulating neutrophils, now defined as B cell helper
neutrophils (NBH), have been shown to colonize the spleen and induce
immunoglobulin class switching, somatic hypermutation, and T-cell-
independent antibody production in B cells by secreting B-cell acti-
vating factor (BAFF), IL-21 and a proliferation-inducing ligand (APRIL)
(Puga et al., 2011; Huard et al., 2008; Cerutti et al., 2013). Moreover,
murine neutrophils can secrete B lymphocyte stimulator (BLyS), thus
prolonging B cell and plasma cell survival (Scapini et al., 2005). There
appear to be inter-species differences in the role of splenic neutrophils
because the above mechanisms identified in mice do not always occur
in humans (Nagelkerke et al., 2014; Scapini and Cassatella, 2017).
The discovery of different subpopulations of neutrophils that po-
larize macrophages in opposite directions indicates that these cells may
not only induce but also suppress immune responses. A subtype of
murine neutrophils with a suppressive phenotype has been identified
(Tsuda et al., 2004). In a mouse model of leishmaniasis, apoptotic
neutrophils that have phagocytosed the parasite were co-localized with
DCs suppressing the adaptive immune response (Peters et al., 2009;
Ribeiro-Gomes et al., 2012). In addition, a subtype of human neu-
trophils acting as granulocytic myeloid-derived suppressor cells (G-
MDSCs) was found to reduce T cell and NK cell proliferation (Youn and
Gabrilovich, 2010; Munder et al., 2005; Kraaij et al., 2010; Nagaraj
et al., 2013). Another neutrophil subtype that inhibits the proliferation
of T cells was identified in patients with systemic inflammation (Pillay
et al., 2012).
Given the prominent role played by neutrophils during infection,
their large array of receptors for the recognition of PAMPs, and the
proposed co-evolution of microbes and immune cells, it is not unlikely
that microbes influence multiple aspects of neutrophil biology. For
example, commensal microbes may control the production of neu-
trophils and their capacity for phagocytosis, raising the opportunity
that these factors also affect the ageing of peripheral neutrophils (Zhang
et al., 2015). Furthermore, neutrophil diversity induced by microbial
products in mice can also affect pathological states. For example,
neutrophils were shown to become more active following the activation
of Toll-like receptors (TLRs) and Myd88, which mediate microbiome-
driven neutrophil ageing. The microbiome may therefore support the
balanced activation status of neutrophils, justifying the evolutionary
pressure to maintain an energy-consuming short lifespan as a me-
chanism to refine the balance between highly active neutrophils and the
risk of tissue injury (Zhang et al., 2015). We therefore speculate that the
imbalanced microbiome (dysbiosis) associated with many neurode-
generative diseases (Jangi et al., 2016; Fung et al., 2017; Marizzoni
et al., 2017) may cause homeostatic neutrophils to be overrun with
more active and/or aging neutrophils, with deleterious effects.
Despite the growing literature drawing attention to the role of sex-
on immune system, most studies have focused on the adaptive immune
system and innate immune cells such as neutrophils have been largely
overlooked (Pennell et al., 2012; Giefing-Kroll et al., 2015; Tan et al.,
2015; Klein and Flanagan, 2016; Gubbels Bupp et al., 2018).
Interestingly, a recent study using a bacterial model of prostate in-
flammation indicated that testosterone promotes the recruitment of
malfunctioning neutrophils that amplify and prolong the inflammatory
response, with the persistence of their toxic products destroying cellular
components and generating a pathogenic environment (Scalerandi
et al., 2018). The authors clearly showed that testosterone inhibits the
bactericidal potential of neutrophils by reducing myeloperoxidase
(MPO) activity and promoting the expression of the anti-inflammatory
cytokines IL-10 and transforming growth factor 1β (TGF-β1), a neu-
trophil phenotype previously reported only in the tumor micro-
environment (Scalerandi et al., 2018).
Taken together, these studies indicate that neutrophils can display
environmental-specific phenotypic and functional plasticity that un-
derpins their pleiotropic effects during homeostasis, but also has the
potential to induce chronic inflammation and/or tissue damage.
Although the diversity of neutrophil subtypes remains unclear, neu-
trophils are now known to be key players in the development of many
chronic inflammatory diseases, including chronic low-grade adipose
tissue inflammation, insulin resistance mediated by the secretion of
elastase, atherosclerosis, rheumatoid arthritis, systemic lupus er-
ythematosus, anti-neutrophil cytoplasmic antibody-related vasculitis,
deep vein thrombosis, chronic obstructive pulmonary disease, cystic
fibrosis, and animal models of MS (Mantovani et al., 2011; Miller et al.,
2015; Caielli et al., 2012; Talukdar et al., 2012; Chmelar et al., 2013).
The pathological significance of the neutrophil subtypes as well as their
regulatory networks, urgently need to be clarified.
2.2. Neutrophil heterogeneity
Neutrophils are a heterogeneous population of cells that rapidly
change their characteristics and behavior when they are activated, as
they age, or when they enter new environments. This is a fundamental
property for the cells, allowing functional specialization and environ-
mental adaptation. The subpopulations of neutrophils are defined by a
combination of features such as the expression of surface markers,
maturity, density, morphology and anatomical site.
When neutrophils leave the bone marrow and enter the peripheral
circulation, integrin α4β1, also known as very late antigen 4 (VLA-4) or
CD49d, and CXCR4 are downregulated, whereas CXCR2 and TLR-4 are
upregulated (Grieshaber-Bouyer and Nigrovic, 2019). Mature human
neutrophils express the neutrophil lineage markers CD15 and CD66b,
along with high surface levels of CD16 (FcγRIII), CD62 L (L-selectin),
and CD10 (neutral endopeptidase) (Elghetany, 2002, Marini, et al.,
2017). Neutrophils change their phenotype following activation, which
involves the surface translocation of pre-formed intracellular pools of
membrane proteins such as β2 integrin CD11b/CD18 (Mac-1), and in
some individuals CD177 (Elghetany, 2002; Goldschmeding et al., 1992;
Videm and Strand, 2004). Activated neutrophils also display comple-
ment surface receptors such as CR1 (CD35), which mediates the binding
and phagocytosis of C3b-coated particles and immune complexes
(Videm and Strand, 2004; Berends et al., 1993). Other surface markers
are lost during activation, including CD62 L. Under conditions of im-
mune stress, immature neutrophils released from bone marrow also
become CD16lo and CD10lo (Marini et al., 2017; Pillay et al., 2010a,b).
In the mouse, a recent report distinguished neutrophil subsets during
inflammation by identifying CD101 (Igsf2) as a marker of mature
neutrophils (Evrard et al., 2018). Indeed, circulating mature neu-
trophils are defined as Ly6G+ CXCR2+ CD101+, whereas immature
neutrophils are defined as Ly6Glo/+CXCR2– CD101–, and are rare in the
circulation under baseline conditions (Evrard et al., 2018).
Aged neutrophils are known to upregulate CXCR4, leading to their
return to the bone marrow for clearance, but they downregulate L-se-
lectin and CD47, an inhibitor of phagocytosis (Adrover et al., 2016). In
mice, the neutrophil marker Ly6G is less abundant in older cells (Zhang
et al., 2015; Rosales et al., 2017). Recently, the surface expression of
other molecules has also been found to increase during neutrophil
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aging, including CD11c, CD24, CD45, and molecules involved in cell
migration and intercellular interactions (CD11b and ICAM-1) (Zhang
et al., 2015; Rosales et al., 2017). Interestingly, ICAM-1 also identifies
neutrophils with enhanced effector functions in murine models of en-
dotoxemia and MS (Whittaker Hawkins et al., 2017; Woodfin et al.,
2016). Neutrophils undergo morphological changes during aging, be-
coming smaller, containing fewer granules, and displaying a granular
multi-lobular nucleus (Casanova-Acebes et al., 2013; Rosales et al.,
2017). Functionally, these cells appear hyper-activated, with the in-
duction of several signaling pathways distinct from those in activated
neutrophils, including TLRs, NOD like receptors (NLRs), and the tran-
scription factor NF-κB, leading to the production of more ROS and the
formation of NETs (Zhang et al., 2015; Adrover et al., 2016). Some
studies have shown that aged neutrophils migrate efficiently to sites of
inflammation (Uhl et al., 2016), whereas others have described im-
paired migration and reduced pro-inflammatory activity in neutrophils
that have been aged in vitro (Rankin, 2010; Whyte et al., 1993). Fur-
thermore, brain injury in a model of induced ischemic inflammation
was only exacerbated in mice enriched with fresh neutrophils, not in
mice with constitutive aged neutrophils, suggesting that fresh neu-
trophils preferentially migrate during brain inflammation contributing
to tissue injury (Adrover et al., 2016). A further subtype of neutrophils
displaying a CD49dhi CXCR4hi profile is efficiently recruited to non-
vascularized tissues under hypoxia, where they support angiogenesis
(Christoffersson et al., 2012; Massena et al., 2015), like the neutrophils
that promote tumor vascularization (Jablonska et al., 2010), further
complicating the classification of neutrophil subtypes based on the
expression of surface markers.
Analysis of the role played by tumor-associated neutrophils in a
variety of human cancers revealed a heterogeneous population with
phenotypes ranging from inflammatory and anti-tumor (N1) to sup-
pressive and pro-tumor (N2), mirroring the nomenclature of macro-
phages with similar activity (Smith and Trinchieri, 2018; Grecian et al.,
2018). N1 neutrophils can kill tumor cells via hypochlorus acid pro-
duced from ROS, via release of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), or via tumor necrosis factor-α (TNF-α) ex-
pression (Dallegri et al., 1991; Andzinski et al., 2016; Tecchio et al.,
2004). In contrast, N2 neutrophils promote tumor growth by increasing
the deposition of extracellular matrix and suppressing the anti-tumor
immune response. However, the binary N1/N2 classification is now
considered an oversimplification, with evidence of greater plasticity
and heterogeneity, and context-dependent differentiation and/or acti-
vation states reflecting the tissue environment, the inflammatory
trigger, and interactions with other cell types (Smith and Trinchieri,
2018; Silvestre-Roig et al., 2016; Jones et al., 2016; Singhal et al., 2016;
Sagiv et al., 2015; Mishalian et al., 2017).
Looking more specifically at the tissue environment, the lung is
populated by large numbers of neutrophils under steady-state condi-
tions, with cells adhering to the vascular lumen and interstitial spaces
(Devi et al., 2013; Zemans et al., 2009). These cells are strategically
positioned in the lungs either to supply the circulation or respond to
injury. Their retention is mediated by CXCR4 signaling, and release into
the blood can therefore be triggered by CXCR4 antagonists or epi-
nephrine (Devi et al., 2013). Alternatively, they promptly infiltrate the
interstitium and airspaces during inflammatory conditions (Kreisel
et al., 2010). It is unknown whether similar strategies are adopted
elsewhere, but neutrophils populating other tissues are also endowed
with homeostatic functions. As stated above, neutrophils can interact
with T cells in the lymph nodes (Hampton et al., 2015), and a sub-
population of human and mouse neutrophils is known to express
functional CCR7, a chemokine receptor involved in the migration of
neutrophils to secondary lymphoid organs (Beauvillain et al., 2011).
Neutrophil migration to lymph nodes also relies on receptors that are
upregulated in aging cells, such as CD11b and CXCR4 (Gorlino et al.,
2014). Interestingly, neutrophils (like T and B cells) can enter lymph
nodes from the peripheral circulation by crossing high endothelial
venules in the context of infection or antigen challenge (Gorlino et al.,
2014; Kamenyeva et al., 2015; Brackett et al., 2013), and intravital
microscopy has identified neutrophils migrating within the lymphatic
vessels of inflamed skin, and localizing to draining lymph nodes in re-
sponse to the injection of microbes (Hampton et al., 2015). Neutrophils
are also involved in T cell-mediated responses through contact-depen-
dent inhibition and the local delivery of ROS (Pillay et al., 2012). No-
tably, low doses of endotoxin trigger the appearance of a T cell-sup-
pressive population of neutrophils in the human peripheral circulation,
and this subtype displays morphological features such as nuclear hyper-
segmentation and the expression of the surface markers CD62Llo,
CD11bhi and CD11chi (Pillay et al., 2012) that resemble aged neu-
trophils in the mouse (Casanova-Acebes et al., 2013; Zhang et al.,
2015). Similarly, large numbers of neutrophils are also found in the
spleens of healthy mice and humans. Human NBH cells display a
CD15int/lo CD16int/lo CD11bhi phenotype, whereas the equivalent po-
pulation in mice are a mixture of immature Ly6Glo cells, which retain
their proliferative capacity but have limited mobility and phagocytic
capacity, and mature Ly6Ghi cells that are highly motile and phagocytic
(Puga et al., 2011; Scapini and Cassatella, 2017; Deniset et al., 2017).
Splenic neutrophils adopt a distinct CD62Llo CD11bhi ICAM-1hi pheno-
type and are found near B cells in the marginal zone, where they have
the tendency to produce NETs and secrete cytokines to induce somatic
hypermutation and antibody production (Puga et al., 2011; Cerutti
et al., 2013).
The density of neutrophils in healthy human subjects is> 1.080 g/
mL, which is slighter greater than the density of peripheral blood
mononuclear cells (PBMCs), such as lymphocytes (1.073–1.077 g/ml)
and monocytes (1.067–1.077 g/ml) (Zipursky et al., 1976). Neutrophils
isolated from the blood by discontinuous density gradient form a red
cell pellet, often described as the high-density or normal-density layer,
and a low-density layer of PBMCs. Normal-density neutrophils (NDNs)
are generally the most abundant cell type in the pellet, but in cancer
patients and individuals with autoimmune diseases, systemic and local
infection, dermatomyelosis, malaria or asthma, there is an expanded
population of neutrophils in the low-density layer, known as low-den-
sity neutrophils (LDNs), which can be further defined by maturity and/
or morphology (Galdiero et al., 2018; Carmona-Rivera and Kaplan,
2013; Villanueva et al., 2011; Singh et al., 2014; Zhang et al., 2017;
Rocha et al., 2015; Fu et al., 2014; Cloke et al., 2012). LDNs tend to be
large and are either immature with banded/ring nuclei or mature with
segmented nuclei, they have a tendency to produce NETs, and an en-
hanced pro-inflammatory profile characterized by the synthesis of cy-
tokines such as IL-6, IL-8, TNFα, and interferon (IFN) type I, meaning
they contribute to neutrophil recruitment and chronic inflammation
(Villanueva et al., 2011; Denny et al., 2010; Kanamaru et al., 2018). In
mice, NDNs can be converted into a distinct LDN subpopulation that
appears to be transient in self-resolving inflammation but accumulates
in animals with tumors (Sagiv et al., 2015).
Overall, these data suggest that neutrophil functionality is de-
termined not only by surface markers but also, independently, by the
anatomical site and inflammatory milieu. Insight into the pathological
role of neutrophils therefore requires a deep characterization of their
functional phenotype. We currently know little about neutrophil het-
erogeneity, hallmark effects, and the detection of mediators that trigger
the conversion from physiological tissue repair and regeneration to
pathological tissue damage. Given the exceptional sensitivity of these
cells to external stimuli, the selection of procedures to analyze neu-
trophils isolated from the blood or tissue environment may influence
their phenotype and/or functional properties, thus contributing to the
increasingly complex and confounding identification of neutrophil
subtypes (Rebecchi et al., 2000; Pallister et al., 2006).
The field will continue to expand, there is far more to be learned
about neutrophils that do much more than simply get sent into the
circulation to capture and digest microbes. This multifaced cell support
homeostasis as well as complex disease states, and display regulatory
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properties that extend beyond their lifetime in the circulation.
3. Neutrophils in MS
MS is a chronic inflammatory disease of the CNS with an auto-
immune origin. It involves progressive myelin degradation by cells of
the immune system, which slows and disrupts the transmission of nerve
impulses (Tillery et al., 2017). MS pathology is also characterized by
well-defined inflammatory infiltrates, the activation of microglia, the
proliferation of astrocytes, gliosis, and variable degrees of axonal de-
generation (Kaskow and Baecher-Allan, 2018; Constantinescu et al.,
2011). This results in clinical manifestations such as changes in sen-
sation, mobility, balance, sphincter function, vision, and cognition. MS
clinical manifestation is heterogeneous, ranging from a mild illness to a
rapidly evolving, incapacitating disease demanding profound lifestyle
adjustments and with major individual and socioeconomic con-
sequences (Aktas et al., 2010; Bishop and Rumrill, 2015; Kobelt et al.,
2019). Globally, MS affects ∼2.5 million people in early to middle
adulthood (mean age at onset= 30 years), and is the most common
chronic demyelinating disease, with a higher prevalence in countries
further from the equator (Dendrou et al., 2015).
Based on the initial disease course, MS can be classified as relapsing-
remitting (RRMS) or primary progressive (PPMS). The most frequent
form of MS is RRMS, affecting more than two-thirds of patients. It ty-
pically affects young adults and features episodes of neurological dys-
function (relapses) lasting at least 24 h in the absence of fever or in-
fection, alternating with periods of remission, which can be variable
and incomplete. One of the hallmarks of RRMS is the presence of focal
inflammatory lesions leading to demyelinated CNS plaques that can be
detected by magnetic resonance imaging (MRI). Most RRMS patients
present with lesions primarily disseminated in the brain, whereas a
small proportion have lesions primarily disseminated in the spinal cord
(Bot et al., 2004; Thorpe et al., 1996; Nociti et al., 2005). RRMS affects
women three times more frequently than men (Brownlee et al., 2017).
After 10–15 years, most RRMS cases evolve into secondary progressive
MS (SPMS), during which there is a gradual loss of ability, with or
without relapses (Dendrou et al., 2015; Lublin et al., 2014; Ontaneda
et al., 2017). The remaining 15% of MS patients present with PPMS, in
which there is a continuous and gradual worsening of neurological
symptoms over time, usually without relapses. In contrast to RRMS, in
which gadolinium-enhancing MRI lesions are common, PPMS patients
present with progressive brain atrophy (Filippi et al., 1997). The final
acute MS phase usually lasts no more than 1 year before death.
Both environmental and genetic factors seem to be involved in MS.
There is a broad consensus that the disease is multifactorial and the MS-
prone genotype results from multiple independent or interacting poly-
morphic genes, with risk alleles common in the population, and each
exerting a small or at most moderate effect. GWAS have identified more
than 100 common genetic variants associated with MS, mostly in loci
related to the adaptive immune system (Hemmer et al., 2015). More-
over, environmental risk factors affecting the immune system, such as
prior infection with Epstein-Barr virus, smoking, and low sunlight ex-
posure/vitamin D deficiency, play a role in the development of MS
(Tillery et al., 2017; Salvetti et al., 2009). The broad heterogeneity in
terms of pathological features and clinical development suggests that
multiple pathogenic pathways contribute to the disease. Two main
hypotheses have been proposed to explain the role of the immune
system in the development of lesions. The “outside-in” hypothesis
suggests that a peripheral antigen-specific immune response, triggered
by foreign antigens, spreads to the initially unaffected CNS. In contrast,
the “inside-out” hypothesis suggests that MS is triggered within the
CNS, leading to the activation of resident microglia followed by the
amplification of the immune response due to the recruitment of ancil-
lary adaptive and innate immune cells (Henderson et al., 2009). In the
latter case, the triggering factor might be a mutation that causes the
death of oligodendrocytes, resulting in the activation of microglial cells
(Hemmer et al., 2015). Inflammation is known to cause tissue damage
in the early stages of the disease because anti-inflammatory and im-
munosuppressive therapies can ameliorate RRMS but not the pro-
gressive forms of the disease (Mahad et al., 2015).
The “outside-in” hypothesis was developed based on studies in mice
with experimental autoimmune encephalomyelitis (EAE), the most
widely used experimental model of the disease. C57BL/6 J and SJL mice
are widely used for the induction of EAE, but different clinical signs are
observed in each strain. SJL mice immunized with the peptide PLP139-
151 develop a disease similar to RRMS, where remission can be com-
plete or partial depending on the severity of the symptoms (McRae
et al., 1995; Vanderlugt et al., 2000). In contrast, C57BL/6 J mice im-
munized with peptide MOG35-55 in complete Freund’s adjuvant (CFA)
manifest a chronic and sustained form of EAE (Bannerman et al., 2005).
Pathogenesis is closely related to the trafficking of autoreactive immune
cells into the CNS via an increasingly dysfunctional blood–brain barrier
(BBB). Myelin-reactive T cells (particularly subtypes Th1 and Th17) are
the principal cell populations that attack myelin sheaths (Korn et al.,
2007; Langrish et al., 2005).
Neutrophil infiltration has been investigated in C57BL/6 J mice
immunized with MOG35-55. Immunohistochemistry and flow cyto-
metry revealed that neutrophils were the most abundant population
immediately before and at the onset of disease, whereas their number
and percentage dropped at the disease peak, when they were found also
in the CNS parenchyma (Fig. 1), and during the phase of recovery
(Soulika et al., 2009; Steinbach et al., 2013; Christy et al., 2013;
Simmons et al., 2014; Rumble et al., 2015; Wu et al., 2010; Aube et al.,
2014). Interestingly, neutrophils appear in meningeal and perivascular
inflammatory foci shortly before the onset of clinical symptoms in the
CNS of mice with active EAE (Steinbach et al., 2013; Christy et al.,
2013). At the disease peak, neutrophils were observed in CNS regions
within areas of vascular leakage, demyelination and axonal damage
(Soulika et al., 2009; Wu et al., 2010), suggesting their detrimental role
in the CNS during the development of EAE. Furthermore, the spinal
cord showed evidence of massive neutrophil accumulation in the center
of and in close proximity to demyelinated areas and sites of axonal loss
or degeneration during the early stages of EAE, but no neutrophil in-
filtration was observed in the CNS of naïve mice (Wu et al., 2010).
These findings suggest that neutrophils promote inflammation during
the onset and progression of EAE, as well as demyelination and axonal
damage during the acute phase of the disease. Notably, in an EAE model
induced in rhesus monkeys (very similar to human MS pathology),
neutrophils consistently infiltrated the CNS as the disease developed
(Bajramovic et al., 2008).
EAE can be attenuated by the direct targeting of neutrophils, in-
terference with their mobilization from the bone marrow, or by
blocking the mechanism of neutrophil recruitment in the inflamed CNS
(Steinbach et al., 2013; Rumble et al., 2015; McColl et al., 1998;
Carlson et al., 2008; Woodberry et al., 2018). Interestingly, neutrophil
depletion attenuates the disease before (but not after) onset or relapse,
suggesting a role for neutrophils in the early phases of lesion devel-
opment (Steinbach et al., 2013; McColl et al., 1998; Carlson et al.,
2008). G-CSF is indirectly responsible for neutrophil mobilization in
response to inflammation (Sadik et al., 2011; Nauseef and Borregaard,
2014), and this molecule accumulates in the CNS and periphery of EAE
mice during the preclinical disease phase, correlating with the greater
number of neutrophils in the bone marrow and bloodstream (Soulika
et al., 2009; Rumble et al., 2015). Mice deficient for the G-CSF receptor
show evidence of neutropenia and are resistant to the induction of EAE
(Rumble et al., 2015). Moreover, treatment with G-CSF prior to the
onset of EAE and during remission aggravates the disease (Verda et al.,
2006). In agreement with these data, the symptoms of MS are also
aggravated in human patients treated with G-CSF (Openshaw et al.,
2000; Burt et al., 2001). The massive infiltration of neutrophils into
CNS lesions occurs following the induction of EAE by the passive
transfer of myelin-specific Th2 and Th17 cells, which secrete GM-CSF
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and IL-17, respectively (Woodberry et al., 2018; Lafaille et al., 1997;
Herges et al., 2012). In agreement with these results, EAE can be
ameliorated by neutrophil depletion, achieved by inhibiting CXCR2-
dependent migration, or by blocking IL-17 and GM-CSF (key mediators
of neutrophil recruitment) (Woodberry et al., 2018).
Although there is no direct experimental evidence showing that
CNS-infiltrating neutrophils can become APCs (Steinbach et al., 2013;
Carlson et al., 2008), neutrophils can induce the maturation of resident
APCs during active EAE by producing pro-inflammatory cytokines such
as TNFα, IFNγ, IL-6, IL-1β and IL-12/23 p40, thus confirming their key
role in pathogenesis (Steinbach et al., 2013; Levesque et al., 2016).
However, the ability of NETs to activate plasmacytoid DCs (Garcia-
Romo et al., 2011; Lande et al., 2011) and myeloid DCs (Sangaletti
et al., 2012) appears to play an important role in some autoimmune
diseases, such as type I diabetes (Diana et al., 2013), systemic lupus
erythematosus (Garcia-Romo et al., 2011; Lande et al., 2011; Barrat
et al., 2005; Means et al., 2005) and psoriasis (Lande et al., 2007),
arguing against a direct role of neutrophil NETosis in the activation and
maturation of resident or migrating APCs in the CNS during EAE. In
agreement with this hypothesis, neutrophils isolated from the CNS of
EAE mice can induce the maturation of in vitro differentiated DCs by
secreting an unidentified soluble factor (Steinbach et al., 2013). Spe-
cifically, neutrophil depletion impaired the maturation of both micro-
glia and macrophages into professional APCs, reducing the amplifica-
tion of early CNS inflammation (Steinbach et al., 2013), a key step in
the development of autoimmune disease via the local re-activation of
myelin-specific T cells (Kawakami et al., 2004). ICAM-1 was recently
identified as a surface marker that distinguishes between intravascular
crawling neutrophils and extravascular CNS-infiltrating neutrophils,
highlighting how molecular changes lead to functional plasticity after
extravasation (Whittaker Hawkins et al., 2017). Once they have ex-
travasated in the CNS, neutrophils acquire macrophage-like im-
munostimulatory and antigen presentation properties in close physical
contact with T and B cells, suggesting a direct role in chronic in-
flammation. The pro-inflammatory enzyme aspartic peptidase retro-
viral-like 1 (ASPRV1) is only expressed by neutrophils inside the CNS,
correlating with the progression from acute to chronic inflammation
during EAE (Whittaker Hawkins et al., 2017). However, it is unclear
whether neutrophils modulate (or are modulated by) lymphocytes
during disease progression.
Another potential mechanism by which neutrophils contribute to
EAE pathology is by facilitating the disruption of the BBB (Steinbach
et al., 2013; Aube et al., 2014). Neutrophil perivascular infiltration has
been observed in hyper-acute MS lesions, which are associated with
areas of BBB leakage (Aube et al., 2014), suggesting that neutrophil
infiltration in the CNS of MS patients may represent an early trigger for
inflammation leading to BBB damage. Such cytotoxic effects may be
contact-dependent or may involve the secretion of cytokines (Levesque
et al., 2016), ROS (Wright et al., 2010; Larochelle et al., 2011), pro-
teases such as MMP9 (Rosenberg, 2002; Agrawal et al., 2006), and
NETs (Allen et al., 2012), as postulated for other neuroinflammatory
conditions (Rosales et al., 2017; Woodberry et al., 2018). Moreover, in
MS patients with active lesions, the abundance and activity of MMP9
increased in the serum and cerebrospinal fluid (CSF) associated with
BBB leakage (Vafadari et al., 2016). Larger numbers of NETs were
found in the blood of some RRMS patients, supporting a role for neu-
trophils in MS pathogenesis, although there was no correlation with
disease severity (Naegele et al., 2012; Tillack et al., 2013). Further-
more, inhibiting the production of ROS (which stimulate the release of
NETs) reduced the severity of EAE and modulated the immune response
(Choi et al., 2015). Neutrophil infiltration has also been reduced by
inhibiting neutrophil elastase and depleting MPO, two enzymes in-
volved in NETosis, attenuating the clinical symptoms of EAE (Herges
et al., 2012; Yu et al., 2018). However, in other studies with MPO-
deficient mice and mice treated with inhibitors of neutrophil elastase,
the course of EAE was not affected in comparison to control mice
(Steinbach et al., 2013). Interestingly, when peripheral neutrophils
were depleted before the induction of EAE, inflammatory cells accu-
mulated in the perivascular space without infiltrating the parenchyma.
This suggests that neutrophils may boost leukocyte recruitment during
EAE, facilitating cell migration from the perivascular space to the brain
parenchyma probably by increasing the permeability of the glia lim-
itans (Simmons et al., 2014).
Phagocytosis by activated macrophages is the major cause of neuron
demyelination during EAE (Rawji and Yong, 2013), but recently-pub-
lished 3D ultrastructural data indicate that neutrophils can also take up
myelin debris via this process (Yamasaki et al., 2014). The molecular
and pathophysiological significance of neutrophil phagocytosis in de-
myelination is still unclear, but CCR2-deficient mice develop EAE be-
cause neutrophil extravasation fulfils the same role as macrophage in-
filtration and the resulting macrophage-dependent phagocytosis and
damage in the CNS (Gaupp et al., 2003; Saederup et al., 2010).
As discussed earlier, neutrophils range in function from pro-in-
flammatory to suppressive, and the presence of the latter in EAE is
supported by the fact that nitric oxide (NO) released by neutrophils
inhibits the proliferation of encephalitogenic T cells in response to
Fig. 1. Neutrophils infiltrate the spinal cord of EAE mice at onset and peak of disease. Representative images of Ly6G+ neutrophils accumulating in the spinal cord at
the onset of disease (a, b), and at the disease peak (b, c). Immunofluorescence staining of the spinal cord in EAE mice using antibodies against Ly6G (green) and
counterstaining with the nuclear dye DAPI (blue). The outlined area in a and c (magnification 20x) is shown at higher magnification (40x) in the adjacent panels b
and d. Scale bar =200 μm (a, c), 10 μm (b, d). Images were acquired using an Axio Imager Z2 (Zeiss, Germany). These figures are unpublished data from G. Constantin’s
laboratory.
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myelin antigen (Zehntner et al., 2005). Moreover, the adoptive transfer
of suppressive neutrophils (G-MDSCs) from the spleen inhibited T cell
activation in the lymph nodes via Programmed death-ligand 1 (PD-L1)-
dependent signaling (Ioannou et al., 2012).
Neutrophils are typically absent from brain samples representing
the most common forms of MS, and the outmoded idea that neutrophils
do not significantly influence the course of this disease are therefore
likely to reflect a sampling bias. The marked increase in the abundance
of neutrophils during the early stages of EAE suggests that these cells
may be more relevant before the clinical manifestation of MS, whereas
tissue sections from MS patients tend to be analyzed long after the
disease is established (Rumble et al., 2015). Accordingly, CSF neu-
trophilia has been reported in studies involving recently-diagnosed MS
subjects and pediatric patients with early-onset MS, respectively
(Chabas et al., 2010; Kostic et al., 2014). The CSF of children with
early-onset MS contained a much greater number of neutrophils com-
pared to pediatric patients with later-onset MS, suggesting that neu-
trophils increase the severity of the disease (Chabas et al., 2010). Sev-
eral indirect observations also link neutrophils to other demyelinating
conditions (Casserly et al., 2017). Infiltrating neutrophils have been
observed in Marburg’s MS patients with diffuse demyelination and ac-
tive vasculitis (Elenein et al., 2011), and in the spinal cords of patients
with optico-spinal MS and active lesions of Devic’s neuromyelitis optica
(Aube et al., 2014; Lucchinetti et al., 2002; Ishizu et al., 2005).
Although CNS tissue samples from most MS patients feature sub-
acute or chronic lesions, blood is characterized by a higher neu-
trophil–lymphocyte ratio (NLR) than healthy blood, and the ratio tends
to increase during relapses or with worsening symptoms (Demirci et al.,
2016, Bisgaard et al., 2017). Larger numbers of circulating neutrophils
with a primed phenotype (such as greater resistance to apoptosis and
Table 1
Summary of experimental evidences of neutrophils involvement in MS.
Study design Main findings concerning neutrophils Putative neutrophil involvement References
Autopsy material from
acute MS patients
Neutrophil perivascular infiltration is observed in hyper-
acute MS lesions associated to BBB leakage.
CNS neutrophils infiltration represents an early
phenomenon in the inflammatory reactions in MS
patients.
Aube et al., 2014
MS patient and MS
pediatric patients
Early-diagnosed MS subjects and early-onset pediatric
patients present CSF neutrophilia.
Neutrophils are most relevant in MS pathogenesis
during preliminary stages. prior to onset or relapses.
Chabas et al., 2010; Kostic et al.,
2014
MS patients MS patients are characterized by a high neutrophil-
lymphocyte ratio (NLR) in the blood, that ratio tends to
increase during relapses or with the worsen of disability.
Elevated number of peripheral neutrophils contributes
to MS exacerbation and relapses. NLR must be
investigated as novel marker of disease activity in
RRMS.




RRMS patients have elevated number of circulating
neutrophils exhibiting a primed state based on reduced
apoptosis, higher expression of TLR-2, CD11b/CD18,
CD10, CD13, fMLP receptor, IL-8 receptor and CD43,
enhanced degranulation of elastases and proteases, ROS
production and higher levels of NETs in serum.
Elevated number of primed peripheral neutrophils
increases BBB permeability, CNS inflammation and
tissue injury contributing to MS exacerbation and
relapses.
Aoki et al., 1984; Guarnieri
et al., 1985; Ziaber et al., 1998;
Naegele et al., 2012; Tillack
et al., 2013
RRMS patients Plasma levels of CXCL5 are elevated during acute lesion
formation. Systemic expression of CXCL1, CXCL5, and
neutrophil elastase correlate with measures of MS lesion
burden and clinical disability.
Neutrophil-related molecules must be investigated as
novel biomarkers in MS.
Rumble et al., 2015
EAE Neutrophils represent the most abundant CNS infiltrating
leukocytes in the in the effector phase of EAE
development.
CNS infiltrating neutrophils are one of the major sources
of inflammatory cells in the early EAE development
having a role in EAE initiation.
Wu et al., 2010; Rumble et al.,
2015
EAE CNS infiltrating neutrophils reduction (depleting
circulating neutrophils or inhibiting neutrophils
mobilization or interfering with neutrophil CNS
recruitment) inhibits or attenuates EAE.
CNS infiltrating neutrophils have a role in preparing
local inflammation.
McColl et al., 1998; Carlson
et al., 2008; Steinbach et al.
2013; Rumble et al., 2015
EAE CNS infiltrating neutrophils correlate with axonal damage
in acute subpial and perivascular lesions.
CNS infiltrating neutrophils contribute to axonal loss in
the earlier stages of EAE.
Soulika et al., 2009
EAE Neutrophils promote blood-CSF barrier breakdown in the
EAE-initiating events.
CNS infiltrating neutrophils allow initial cells migration
into the meninges promoting vascular permeability.
Christy et al., 2013; Aube et al.,
2014
EAE Neutrophils differently migrate in brain and spinal cord: Il-
17 promotes ELR-motif CXC chemokines expression on
neutrophils and their recruitment in the brain while IFN-γ
promotes their ELR-motif CXC chemokines mediated
migration in the spinal cord.
Brain and spinal cord exhibit distinct sensitivities to
cellular mediators of tissue damage: brain but not in
spinal cord, is neutrophil infiltration dependent.
Simmons et al., 2014
EAE ICAM-1 + neutrophils are preferentially recruited in the
CNS during EAE. Neutrophils once extravasated in the CNS
acquire macrophage-like immunostimulatory and antigen
presentation properties in close physical contact with T
and B lymphocytes Proinflammatory enzyme ASPRV1 is
only expressed by neutrophils inside the CNS and
correlates to the progression from acute to chronic
inflammation.
ICAM1+ macrophage–like neutrophils have a direct
role in antigen presentation and in perpetuation of
chronic inflammation via ASPRV1 activity.
Whittaker et al. 2017
EAE CNS-infiltrating neutrophils mature bone marrow-derived
DCs by proinflammatory molecules secretion in vitro.
Depletion of neutrophils impaired maturation of microglia
and macrophages into professional APCs during EAE.
CNS infiltrating neutrophils promote resident APCs
maturation and the development of EAE through the
local re-activation of myelin-specific T cells.
Steinbach et al., 2013
EAE CCR2 deficient mice are susceptible to EAE induction
because inflammation and demyelination are supported by
neutrophils that infiltrate CNS in a high number to
compensate inhibited monocyte recruitment.
CNS infiltrating neutrophils contribute to
demyelination.
Gaupp et al., 2003
EAE IL-1R1 and IL-1β deficient mice are resistant to EAE;
adoptive transfer of WT IL-1β producing neutrophils
restores IL-1R1 deficient mice to sensitivity in EAE
induction.
IL-1β producing activated neutrophils stimulate CNS
vascular endothelium to produce cytokines and
chemokines promoting a positive feedback in the
recruitment of neutrophils and monocytes in the CNS.
Levesque et al., 2016
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enhanced effector mechanisms) were observed in RRMS patients com-
pared to healthy controls (Rumble et al., 2015; Naegele et al., 2012).
Circulating neutrophils in MS patients also produce more ROS (Naegele
et al., 2012), secrete greater amounts of the protease medullasin and
neutrophil elastase (Guarnieri, et al., 1985, Aoki et al., 1984), and ex-
press higher levels of CD11b/CD18, CD10, CD13 (Ziaber et al., 1998),
TLR-2 and N-formylmethionyl-leucyl-phenylalanine receptor (Naegele
et al., 2012; Hertwig et al., 2016) as the disease becomes more severe.
Neutrophils may therefore trigger disease progression not only after
invading the CNS but also from the periphery. Neutrophil activation
within the bone marrow during MS could promote the mobilization of
monocytes and neutrophils themselves in the bloodstream, thus in-
creasing the number of myeloid cells ready to migrate to the CNS (Singh
et al., 2012). Accordingly, serum from MS patients contains sig-
nificantly higher levels of the neutrophil chemoattractant CXCL8/IL-8,
supporting a role for neutrophil recruitment in the disease (Campbell
et al., 2010). During relapses, the plasma of MS patients contains higher
levels of CXCL1, CXCL5, neutrophil elastase and CD11b/CD18 com-
pared to patients in remission, healthy controls and patients with non-
inflammatory neurological diseases (Aoki et al., 1984; Ziaber et al.,
1998). The pathogenicity of human neutrophils in autoimmune de-
myelinating diseases is also suggested by the exacerbation of symptoms
in patients with optico-spinal MS and neuromyelitis optica when
treated with recombinant G-CSF, which is known to mobilize neu-
trophils from the bone marrow (Openshaw et al., 2000; Jacob et al.,
2012). As described above for EAE, circulating neutrophils with a
suppressive phenotype have also been detected during MS. Granulo-
cytic myeloid derived suppressor cells (G-MDSCs) are more abundant in
RRMS patient compared to healthy controls, and increased during re-
lapses (Ioannou et al., 2012). Although their immunoregulatory me-
chanisms are not yet understood, G-MDSCs may contribute to MS
clinical recovery.
In conclusion, the data summarized above suggest that the inter-
actions between neutrophils and cells of the adaptive immune system
play a key role in the pathogenesis of EAE (Aube et al., 2014) and MS
(Rumble et al., 2015). The data from MS and EAE models demonstrate
the potential harmful nature of neutrophils (Table 1), highlighting the
need to understand their role in more detail and suggesting that in-
terfering with neutrophil-dependent tissue damage may offer a pro-
mising therapeutic approach for MS patients.
4. Neutrophils in AD
AD is the most common neurodegenerative cause of dementia in the
elderly, accounting for 72% of cases (Querfurth and LaFerla, 2010;
Calderon-Garciduenas and Duyckaerts, 2017). Sporadic AD usually
occurs in elderly people, whereas familial AD tends to begin before 60
years of age. Both the familial and sporadic forms of AD share a
common phenotype converging towards similar neuropsychiatric
symptoms, emotional disturbance, and the progressive impairment of
normal activity, resulting in dependence, disability and mortality
(Cummings, 2004). With the progression of the disease, neuronal loss
occurs in the most affected areas, and macroscopic atrophy becomes
evident in the entorhinal area and hippocampus, amygdala, and asso-
ciative regions of the neocortex. AD pathogenesis is characterized by
numerous features such as the accumulation of aggregated β-amyloid
peptides (Aβ), the intracellular aggregation of hyperphosphorylated tau
to form neurofibrillary tangles, oxidative stress, inflammation, and
changes in innate immune signaling. There is currently neither a cure
nor adequate clinical treatment for AD and it remains unclear how AD
originates and propagates through the brain.
AD was traditionally viewed as a primary neurodegenerative dis-
order that specifically affects the CNS, but there is now evidence that
brain dysfunctional is closely associated with peripheral inflammatory
signals (Morris et al., 2014; Wang et al., 2017a). AD-related in-
flammation develops in the blood and the brain, separate compartments
that make contact via the BBB. Notably, the BBB clears potentially
neurotoxic molecules from the cerebral parenchyma to the blood, and
regulates the passage of essential nutrients and leukocytes into the CNS
(Zenaro et al., 2017; Abbott et al., 2006; Zlokovic, 2008, 2011). In
patients with early cognitive dysfunction, the BBB breaks down in the
hippocampus, which is critical for learning and memory (Nation et al.,
2019). Thus, the BBB impairment hampers the conventional clearance
of Aβ that accumulate in the brain (Zlokovic, 2011) and in the vessel
walls, inducing the upregulation of adhesion molecule expression on
brain endothelial cells and the release of inflammatory mediators such
as complement system peptides, chemokines and cytokines, likely
promoting the leukocyte recruitment. Tau protein may also play a part
in the BBB breakdown, and its dysfunction correlates with perivascular
tau accumulation in main blood vessels in hippocampus in vivo
(Forman et al., 2005; Kovac et al., 2009; Blair et al., 2015). Ad-
ditionally, misfolded protein tau modifies the endothelial properties of
the BBB, facilitating blood-to-brain cell transmigration (Majerova et al.,
2019; Zilka et al., 2009). These findings suggest that neuro-inflamma-
tion triggered by tau and Aβ promotes the expression of leukocyte-
binding receptors on the endothelial cell surface and damages the cells
of the neurovascular unit, disrupting the integrity of the BBB and the
permeability of blood vessels that facilitate the infiltration leukocytes
into the brain, contributing to disease progression and neurodegen-
eration (Zenaro et al., 2015; Banks, 2015; Di Marco et al., 2015;
Sweeney et al., 2018).
Activated resident sentinel cells in the CNS, such as microglia and
astrocytes, may release tissue danger signals, cytokines and chemokines
that recruit leukocytes from the peripheral circulation to inflammation
areas in the CNS (Zenaro et al., 2017; Abbott et al., 2006; Zlokovic,
2008, 2011; Heneka et al., 2015). A combination of experimental and
clinical evidence, including our own research, suggests that T cells and
neutrophils migrate into the AD brain (Zenaro et al., 2015; Togo et al.,
2002; Town et al., 2005; Ferretti et al., 2016). Although neutrophils
may play a key role in AD, few studies have directly investigated this
phenomenon (Zenaro et al., 2015; Pietronigro et al., 2017; Cruz
Hernandez et al., 2019; Baik et al., 2014). Circulating neutrophils from
AD subjects express higher levels of CD11b in comparison to healthy
subjects, indicating that the adhesion of neutrophil and their brain in-
filtration may correlate with the severity of the disorder (Scali et al.,
2002). Recent clinical data revealing greater numbers of neutrophils or
a higher NLR associated with AD suggest that changes in the neutrophil
population could be used as markers of AD-related peripheral in-
flammation (Kuyumcu et al., 2012; Shad et al., 2013; Rembach et al.,
2014). Peripheral blood neutrophils in AD patients also produce greater
quantities of ROS than controls, suggesting that neutrophils may exist
in a more activated state during AD (Vitte et al., 2004). In agreement
with these findings, a recent pilot study aiming to characterize the
phenotype of human peripheral neutrophils at different stages of AD
revealed a greater neutrophil hyper-activation state in fast-decliner
compared to slow-decliner patients (Dong et al., 2018). In these pa-
tients, the ratio between the harmful aged neutrophils (CXCR4hi
CD62Llo) and the CD16bright CD62Ldim immunosuppressive neutrophil
subsets rose during the later stage of the disease, indicating changes
that may play an instrumental role in establishing systemic chronic
inflammation (Dong et al., 2018). These data strongly suggest that the
hyper-reactive phenotype of circulating neutrophils correlates with the
rate of cognitive decline, potentially offering a prognostic blood bio-
marker in AD patients (Dong et al., 2018). Other studies reported the
higher expression of αM CD11b integrin, HLA-DR and COX1 in the
neutrophils of AD patients (Scali et al., 2002; Fiala et al., 2005), also
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supporting the hypothesis of neutrophil hyper-activation. These data
have been confirmed in patients with a diagnosis of mild AD, where the
neutrophils were shown to upregulate CD177 (Le Page et al., 2017), a
Ly6/uPAR family member and well-known marker of neutrophil acti-
vation (Xie et al., 2015; Stroncek et al., 2004; Hu et al., 2009). Inter-
estingly, CD177 is known to associate with β2 integrins and actively
bind CD31 (PECAM-1) expressed by endothelial cells, thus probably
stimulating neutrophil transmigration (Stroncek, 2007; Sachs et al.,
2007; Bai et al., 2017). These results also suggest that the interaction
between CD177 and CD31 could serve to recruit neutrophils into the
brain parenchyma of AD patients, in a manner similar to that reported
for ICAM-1 and LFA-1 (Zenaro et al., 2015).
Amyloid precursor protein (APP) was recently shown to be ex-
pressed at higher levels in the granulocytes of AD subjects compared to
healthy subjects, whilst there was no statistically significant variation in
peripheral blood mononuclear cells, indicating that the high expression
of APP in granulocytes could be utilized for the early detection of dis-
ease (Wang et al., 2016). Others recently published that neutrophil
functions and granulocyte density from AD subjects differ compared to
healthy controls, thus proposing the characterization of blood neu-
trophils as the opportunity to discover new AD biomarkers (Jaremo
et al., 2013; Le Page et al., 2015). Notably, this activated phenotype of
neutrophils in the peripheral circulation may promote their interactions
in the vasculature and brain parenchyma, as shown in multiple mouse
models of AD (Zenaro et al., 2015; Cruz Hernandez et al., 2019; Baik
et al., 2014). We found that integrin LFA-1 controls the in-
traparenchymal motility and intravascular adhesion of neutrophils in
the cerebral microcirculation of 3xTg-AD transgenic mice, a prominent
animal model of AD (Zenaro et al., 2015). The blockade of the integrin
LFA-1 in 3xTg-AD mice during the early disease phase prevented neu-
trophil adhesion and brain infiltration, and reduced the neuropatholo-
gical hallmarks of AD, hence re-establishing cognition. Our data also
revealed that early treatment with anti-Gr1, anti-Ly6G or anti-LFA-1
antibodies, which deplete neutrophils or inhibit their adhesion, led to a
persistent improvement in cognitive performance (Zenaro et al., 2015).
Of note, the temporary blockade of the integrin LFA-1 during the first
disease phase improve cognitive function also in older mice, thus in-
dicating that the early therapeutic intervention to inhibit neutrophil
recruitment may extend beneficial effects in subjects with AD. In ad-
dition, the genetic depletion of the integrin LFA-1 in 3xTg-AD mice
showed amelioration in behavioral test performance and in the severity
of microgliosis in comparison to wild-type control mice (Zenaro et al.,
2015). Neutrophil may damage brain tissue through several in-
dependent mechanisms, such as premature activation during migration,
extracellular release of toxic products or failure to terminate in-
flammatory responses. However, the functions of neutrophils in AD
remain elusive, and deserve a deeper investigation to elucidate new
mechanisms by which neutrophils might contribute to AD. Interest-
ingly, massive neutrophil accumulation in the brains of 3xTg-AD mice
coincides with the onset of memory loss in cognitive tests at 6 months of
age (Zenaro et al., 2015), but neutrophils also infiltrate the brain at
8–10 months of age, suggesting that neutrophils play a role in the in-
duction of cognitive decline as well as in disease progression. In
agreement with our data, the inhibition of neutrophil adhesion using
anti-Ly6G antibodies in APP/PS1 mice with established cognitive im-
pairment (at 15–16 and 21–22 months of age) rapidly improved cere-
bral blood flow and performance in short-term memory tasks, sug-
gesting neutrophils also play a role in disease progression (Cruz
Hernandez et al., 2019).
Gr1+ cells infiltrate the brain parenchyma and migrate toward Aβ
plaques in the 5xFAD transgenic mouse model of aggressive amyloi-
dosis (Zenaro et al., 2015; Baik et al., 2014). Our two-photon laser-
scanning microscopy experiments in this model revealed neutrophil
swarming in blood vessels adjacent to Aβ plaques, and neutrophil ex-
travasation inside the cerebral parenchyma preferentially in Aβ-rich
areas, suggesting that Aβ might be involved in neutrophil recruitment
and movement inside the brain parenchyma (Zenaro et al., 2015).
Neutrophils typically access sites of infection or tissue damage via the
circulation by following multiple chemoattractant cues and responding
to local inflammatory mediators. The Aβ accumulating in the brain may
represent an ‘end-target’ chemoattractant binding to the FPR1 receptor
prevailing over ‘intermediate’ chemokines in the recruitment of neu-
trophils, likely providing the directional bias observed for many neu-
trophils infiltrated in the brains of AD mouse models (Zenaro et al.,
2015; Phillipson and Kubes, 2011; Tiffany et al., 2001). The association
of neutrophils with Aβ deposits was first reported 30 years ago, when
Aβ deposits in the brain parenchyma and cerebral blood vessels of AD
patients were shown to be associated with cells expressing the neu-
trophil-specific protease cathepsin G, confirming neutrophil accumu-
lation in the CNS of AD patients (Savage et al., 1994). Aβ in AD patients
was also proposed to trigger the expression of CAP37, an inflammatory
mediator constitutively expressed in neutrophils, but the link with
neutrophils was not discussed (Pereira et al., 1996, Grammas, 2000;
Brock et al., 2015). CAP37 was specifically detected in brain regions
that experience the greatest atrophy during AD (temporal, parietal and
frontal lobes) (Serrano-Pozo et al., 2011), but not in age-matched
controls or patients with other neuropathological conditions such as
Pick’s disease, Binswanger’s disease, supranuclear palsy or PD, thus
underlining the strict association of neutrophils with AD pathogenesis
(Pereira et al., 1996; Grammas, 2000; Brock et al., 2015). CAP37 was
also detected in the hippocampal cerebral microvasculature of AD pa-
tients (Pereira et al., 1996), and it is well known that CAP37 released
Fig. 2. Infiltrating MPO+ cells in the human AD brain. Immunofluorescence staining of the hippocampus of a human AD patient, using antibodies against Aβ (red)
and MPO (green), counterstained with the nuclear dye DAPI (blue). The outlined area in (a) (magnification 20x) is shown at higher magnification (40x) in the
adjacent panel (b). Scale bar =30 μm (a), 15 μm (b). Images were acquired using an SP5 tandem confocal microscope (Leica, Germany). These figures are unpublished
data from G. Constantin’s laboratory.
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from the azurophil granules of activated neutrophils may attach to
vascular endothelial cells to prepare the neutrophil for its extravasation
into infected or injured tissue (Morgan et al., 1991). While attached to
the proteoglycans on vascular endothelial cells, CAP37 recruits and
activates monocytes, and increases the expression of adhesion mole-
cules on endothelial cells. This promotes the adherence and extra-
vasation of additional neutrophils and monocytes, thus perpetuating
their recruitment into the AD brain.
We recently identified MPO+ cells infiltrating the brain par-
enchyma of AD patients, followed by their localization typically within
50 μm of Aβ plaques (Zenaro et al., 2015) (Fig. 2). Like CAP37, MPO is
a major protein in the azurophil granules of neutrophils. The distribu-
tion of MPO+ cells in brain tissue was non-random, suggesting that Aβ
may play a chemoattractant role by establishing a favorable micro-
environment for the brain infiltration of neutrophils, thus favoring their
pro-inflammatory function (Zenaro et al., 2015). Neutrophils actively
release MPO by degranulation, but the enzyme is also released during
cell death (van der Veen et al., 2009). MPO activity produces hypo-
chlorous acid and other chlorinated species, which are effective mi-
crobicidal agents but also cytotoxic, thus contributing to neuro-
pathology and disease progression (Ray and Katyal, 2016).
Interestingly, the recent comparison of various brain regions in neu-
rologically healthy individuals and AD patients revealed MPO+ cells in
brain regions affected by neuronal death, thus supporting a role for this
enzyme in neurodegeneration (Gellhaar et al., 2017).
We have previously used various stains to confirm the presence of
neutrophils in the brains of AD mice and human AD patients (and not in
age-matched controls), including (i) hematoxylin and eosin staining to
highlight the presence of the characteristic polysegmented nuclei in
cells that have migrated perivascularly or within the parenchyma
(Zenaro et al., 2015), (ii) napthol AS-D chloroacetate esterase staining
to confirm the presence of cells of the granulocytic lineage (Uchida
et al., 2009; Khandoga et al., 2009), and (iii) staining for the neutrophil-
specific marker CD66b (Zenaro et al., 2015). The brains of human AD
patients also show evidence of intraparenchymal migrated neutrophils
releasing MPO, neutrophil elastase and citrullinated histone H3, which
are required for NETosis (Zenaro et al., 2015). Our findings were also
confirmed by a recent pilot study showing that the harmful hyper-re-
active neutrophil phenotype in the peripheral circulation of AD patients
is associated with the increased production of ROS and intravascular
NETs (Dong et al., 2018). These data suggest that NETs may represent a
neutrophil-dependent disease mechanism that potentially causes by-
stander damage in patients with AD.
The highly reactive phenotype of extravasated neutrophils can
cause chronic collateral tissue damage even if only a few cells migrate
within tissues during a low-grade chronic sterile inflammation.
Notably, intravascular adhesion per se in the absence of transmigration
through the BBB is sufficient to induce endothelial injury (Fabene et al.,
2008; DiStasi and Ley, 2009; Zarbock and Ley, 2008). Our data support
this assumption, in fact the blockade of the integrin LFA-1, known to
regulate the intravascular adhesion of neutrophils, restore cognitive
impairment and neuropathological lesions in murine models of AD
(Zenaro et al., 2015). In agreement, a recent report in APP/PS1 mice
showed that an anti- Ly6G antibody removed capillary stalls resulting
from the intravascular accumulation of neutrophils, improving spatial
and working short-term memory within 3 h from the onset of treatment
(Cruz Hernandez et al., 2019).
Overall, AD is now recognized as a complex systemic disorder
characterized by chronic inflammation involving both the innate and
adaptive immune systems, highlighting the need to investigate the role
of circulating leukocytes in the management of the disease. The role of
neutrophil functional plasticity in AD (Table 2) requires future long-
itudinal studies to discover new therapeutic approaches for the treat-
ment of early symptoms and to monitor disease progression.
Table 2
Summary of experimental evidences of neutrophils involvement in AD.
Study design Main findings concerning neutrophils Putative neutrophils involvement References
Autopsy material from
AD patients
CNS infiltrating neutrophils releasing MPO, NE and citrullinated
histone H3, essential components involved in NETosis.
CNS neutrophils infiltration represents a phenomenon in the
inflammatory reactions in AD patients.
Zenaro et al., 2015
AD patients CNS infiltrating neutrophils express inflammatory mediator
CAP37.
Infiltrating neutrophils promote perpetuating recruitment of
additional neutrophils and monocytes, into the brain by CAP37
contributing to neuronal injury in AD.
Pereira et al.,
1996;
Brock et al., 2015
AD patients AD patients are characterized by a high neutrophil-lymphocyte
ratio (NLR) in the blood, that ratio tends to increase during
relapses or with the worsen of disability.
Elevated number of peripheral neutrophils contributes to AD
neurodegeneration and pathogenesis. NLR must be investigated
as markers of AD-related peripheral inflammation.
Kuyumcu et al.,
2012
AD patients AD patients have high number of circulating neutrophils
exhibiting a primed state based on over expression of CD11b,
CD177, HLA-DR, COX-2 and NETs and elevated levels of ROS
production. Activation markers in neutrophils positively correlate
with disease severity and progression rate of mental decline.
Elevated number of activated peripheral neutrophils increases
BBB permeability, CNS inflammation contributing to
neurodegeneration and clinical progression of AD.
Neutrophils activation markers must be investigated as
biomarkers of AD-related peripheral inflammation.
Scali et al., 2002;
Vitte et al., 2004;
Fiala et al., 2005;
Shad et al., 2013;
Dong et al., 2018;
Le Page et al.,
2017
AD patients AD patients have high expression of APP in circulating
neutrophils.
APP expression level in peripheral blood granulocyte is a
potential biomarker for early diagnosis of AD.
Wang et al., 2016
AD patients In the blood of AD patients harmful aged neutrophils
(CXCR4high/CD62Llow) and immunosuppressive neutrophil
(CD16bright/CD62Ldim) ratio increases in the later stage of the
disease.
Aged related changes in neutrophils phenotype and activity,
plays a role in establishing systemic chronic inflammation
during AD.
Dong et al., 2018
Mouse models Neutrophils infiltrate the CNS where they produce NETs and IL-
17.
CNS infiltrating neutrophils are one of the major sources of
inflammatory cells in the early AD-like development.
Zenaro et al., 2015
Mouse models Neutrophils are attracted from the blood vessels into CNS by
chronic Aβ deposition and accumulated preferentially in Aβ-rich
areas.
Neutrophil responses to senile plaques influence the progress of
AD.
Baik, et al., 2014;
Zenaro et al., 2015
Mouse models Brain infiltrating neutrophils reduction (depleting circulating
neutrophils or interfering neutrophil CNS recruitment by LFA-1
inhibition) reduce AD-like neuropathology and improve memory.
CNS infiltrating neutrophils have a role in preparing local
inflammation contributing to AD-like pathogenesis and
cognitive impairment.
Zenaro et al., 2015
Mouse models Prevent neutrophil adhesion on cortical capillaries (depleting
circulating neutrophils) restore cerebral blood flow and improve
memory.
Neutrophils indirectly promote cognitive impairment of AD-
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5. Neutrophils in other neurodegenerative diseases
PD is a long-term disorder of the CNS classically associated with
Lewy bodies and the loss of dopaminergic neurons in the substantia
nigra of the midbrain. Like AD and MS, systemic chronic inflammation
may also play an important role in pathogenesis and progressive neu-
rodegeneration (Ferrari and Tarelli, 2011). PD is not restricted to the
dopaminergic system, indeed it involves extensive regions of the ner-
vous system, and is characterized by protein aggregates other than
Lewy bodies (Kalia and Lang, 2015). Disease symptomatology is het-
erogeneous, with clinically significant non-motor features. The diag-
nosis of PD is challenging, and new biomarkers are therefore needed.
The NLR is a widely used marker to detect subclinical inflammation,
and the NLR is higher than normal in PD patients and correlates with
serum levels of C-reactive protein, another marker of peripheral in-
flammation (Akil et al., 2015). However, in one of the few studies
evaluating different types of PD (idiopathic, akinetic-rigid and tremor-
dominant), there was no statistically significant difference in the NLR
(Atac Ucar et al., 2017). Accordingly, a recent report involving early-
stage PD patients found no changes in immune responses of circulating
innate leukocytes, with neutrophil and lymphocyte adherence, che-
motaxis, phagocytic capacity, and NK cytotoxic activity similar to age-
matched healthy subjects (Vida et al., 2019). However, MPO was shown
to be upregulated in damaged areas (ventral midbrain) in human PD
patients and mice treated with 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP), a common animal model of induced PD (Choi
et al., 2005). The same authors also demonstrated that ventral midbrain
dopaminergic neurons in MPO–/– knockout mice are more resistant to
MPTP-induced cytotoxicity than in wild-type controls, suggesting that
MPO inhibitors may provide a protective benefit in PD. In agreement,
MPO+ cells were shown to accumulate in brain regions affected by
neurodegeneration in PD, supporting a role for MPO in neuronal toxi-
city (Gellhaar et al., 2017). However, more evidence is needed to es-
tablish the role of neutrophils in the development and progression of PD
in order to identify the mechanism of pathogenesis as well as potential
therapeutic targets.
ALS is another motor neuron disease with a strong neuroin-
flammatory component, but the inflammatory mechanisms influencing
peripheral motor axon degeneration remain largely unknown (Chiot
et al., 2019). ALS is perhaps the most devastating neurodegenerative
condition because of its insidious onset, rapid progression, and in-
evitable endpoint. Only 5–10% of ALS cases are familial, and the
etiology of the majority sporadic cases remains to be defined (Zufiria
et al., 2016). A prospective cohort study involving ALS patients re-
vealed systemic low-grade inflammation, detected as significant in-
creases in the erythrocyte sedimentation rate, fibrinogen levels, C-re-
active protein concentrations, leukocyte counts and NLR, correlating
with the degree of disability (Keizman et al., 2009). Changes in CD4+ T
cell and neutrophil counts also correlate with rapid disease progression,
suggesting that these leukocytes may contribute to the pathologic fea-
tures of ALS (Murdock et al., 2017). These results were also supported
by blood profiling, which identified low-grade neutrophilia and hy-
poxia as new biomarkers for the disease (Swindell et al., 2019). Inter-
estingly, mast cells and neutrophils accumulate around motor axons in
the extensor digitorum longus muscle, sciatic nerve, and ventral roots of
symptomatic SOD1G93A rats (an animal model of ALS), indicating that
leukocyte infiltration extends along the entire peripheral motor
pathway (Trias et al., 2018).
More work is required to define the profile of immune cell sub-
populations during the course of PD and ALS to identify suitable bio-
markers and therapeutic targets.
6. Conclusion
Neutrophils were once regarded as simple phagocytic cells of the
innate immune system, but are now understood to be an important
component of the effector and regulatory circuits that control the
magnitude and quality of an immune response. A large body of evi-
dence indicates that neutrophils contribute to neural damage in neu-
rodegenerative disorders, particularly MS and AD. However, the me-
chanisms of neutrophil transmigration, accumulation and tissue
damage inside the CNS parenchyma during neurodegeneration are
largely unknown. The phenotype and functional characteristics of
neutrophils in neurodegenerative disorders remain to be established,
partly because it has been difficult to identify neutrophils selectively
until the last 10 years. The growing capacity for single-cell analysis in
immune cell populations and recent platforms for multicolor flow cy-
tometry and next-generation sequencing will therefore provide im-
portant insights into the heterogeneity of neutrophils in neurodegen-
erative disorders.
The heterogeneity and plasticity of neutrophils and their access to
the inflamed CNS represent opportunities for therapeutic intervention,
which may apply to MS and AD but also to other neurodegenerative
diseases. This diversity of neutrophil phenotypes may allow the selec-
tive targeting of pathogenic neutrophils without perturbing those en-
gaged in antimicrobial defense. Further understanding of neutrophil
biology will provide new opportunities for the selective manipulation of
this lineage, as recently explored in the treatment of cancer. Indeed,
several studies involving experimental tumor models have contributed
to our understanding of neutrophil functions in cancer progression,
which may lead to the development of therapies that block the mi-
gration of suppressive neutrophils to the tumor (Movassagh et al., 2017;
Xie et al., 2017), disrupt their reprograming (Sahakian et al., 2017;
Wang et al., 2017a,b), or exploit their spontaneous migration to the
tumor for the delivery of anti-cancer drugs (Kang et al., 2017; Chu
et al., 2017).
Neutrophil phenotyping and the investigation of neutrophil dy-
namics following their recruitment to the CNS during the development
and progression of neurodegenerative diseases will therefore offer the
opportunity to determine the mechanisms of pathogenesis and to
identify novel therapeutic targets.
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